Trends in pathology diagnoses during 10 years of a colorectal cancer screening programme.
colorectal cancer
pathology
screening
serrated polyps
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
10
07
2023
received:
09
05
2023
accepted:
16
07
2023
medline:
5
10
2023
pubmed:
11
8
2023
entrez:
11
8
2023
Statut:
ppublish
Résumé
We report pathology findings from the first 10 years of the faecal-occult blood-based Northern Ireland Bowel Cancer Screening Programme, presenting summary data and trends in pathology diagnoses and clinicopathological features of screen-detected cancers. Data were analysed from a comprehensive polyp-level pathology database representing all endoscopy specimens from programme inception in 2010 until 2021. A total of 9800 individuals underwent 13 472 endoscopy procedures, yielding 25 967 pathology specimens and 32 119 diagnoses. Index specimen diagnoses (4.1%) and index colonoscopies (10.4%) yielded a diagnosis of colorectal cancer, representing 1045 cancers from 1020 individuals (25 with synchronous cancers). A further 13 index cancers were identified via computed tomography colonography; 65.3% of cancer diagnoses were in males; 41.7% were stage I, 23.1% stage II, 25.8% stage III and 1.8% stage IV (7.6% unstaged). Of 233 pT1 cancers diagnosed within local excision specimens, 79 (33.9%) had completion surgery. Ten-year trends showed a steady decline in the proportion of index colonoscopies that yielded a diagnosis of cancer (14.7% in year 1; 4.8% in year 11) or advanced colorectal polyp. There was a strong upward trend in diagnoses of sessile serrated lesions, which overtook hyperplastic polyps in proportions of total index diagnoses by the end of the study time-frame (8.7% compared to 8.5%). Over the first 10 years of a population colorectal cancer screening programme, 'real world' pathology data demonstrate success in the form of reduced diagnoses of cancer and advanced colorectal polyp with passage of successive screening rounds. Interesting trends with respect to serrated polyp diagnoses are also evident, probably related to pathologist and endoscopist behaviour.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
756-770Subventions
Organisme : BHSCT Diagnostic and AHPs Charitable Fund
Informations de copyright
© 2023 The Authors. Histopathology published by John Wiley & Sons Ltd.
Références
Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021; 71; 209-249.
Schreuders EH, Ruco A, Rabeneck L et al. Colorectal cancer screening: a global overview of existing programmes. Gut 2015; 64; 1637-1649.
Loughrey MB, Shepherd NA. The pathology of bowel cancer screening. Histopathology 2015; 66; 66-77.
Cairns S, Scholefield JH. Guidelines for colorectal cancer screening in high risk groups. Gut 2002; 51(Suppl 5); V1-V2.
Rutter MD, East J, Rees CJ et al. British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines. Gut 2020; 69; 201-223.
Kaminski MF, Robertson DJ, Senore C, Rex DK. Optimizing the quality of colorectal cancer screening worldwide. Gastroenterology 2020; 158; 404-417.
UK Colorectal Cancer Screening Pilot Group. Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. BMJ 2004; 329; 133.
Logan RFA, Patnick J, Nickerson C et al. Outcomes of the bowel cancer screening programme (BCSP) in England after the first 1 million tests. Gut 2012; 61; 1439-1446.
Cairns SR, Scholefield JH, Steele RJ et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010; 59; 666-689.
Altobelli E, Lattanzi A, Paduano R, Varassi G, di Orio F. Colorectal cancer prevention in Europe: burden of disease and status of screening programs. Prev. Med. 2014; 62; 132-141.
Quirke P, Risio M, Lambert R, von Karsa L, Vieth M. Quality assurance in pathology in colorectal cancer screening and diagnosis-European recommendations. Virchows Arch. 2011; 458; 1-19.
Steele RJC, McClements P, Watling C et al. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site. Gut 2012; 61; 576-581.
Morris EJA, Whitehouse LE, Farrell T et al. A retrospective observational study examining the characteristics and outcomes of tumours diagnosed within and without of the english NHS bowel cancer screening programme. Br. J. Cancer 2012; 107; 757-764.
Morgan E, Arnold M, Gini A et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 2023; 72; 338-344.
Brenner H, Haug U, Hundt S. Sex differences in performance of fecal occult blood testing. Am. J. Gastroenterol. 2010; 105; 2457-2464.
Coleman HG, Hawkins ST, Gavin AT. Northern Ireland Colorectal Cancer Audit. Measuring the quality of care for patients diagnosed 2018. Belfast: N.Ireland Cancer Registry, Queen's University, 2022.
Dykstra MA, Gimon TI, Ronksley PE, Buie WD, MacLean AR. Classic and novel histopathologic risk factors for lymph nnode metastasis in T1 colorectal cancer: a systematic review and meta-analysis. Dis. Colon Rectum 2021; 64; 1139-1150.
Scott N, Cairns A, Prasad P et al. Resection margin involvement after endoscopic excision of malignant colorectal polyps: definition of margin involvement and tumour recurrence. Histopathology 2023; 83; 80-90.
Zwager LW, Moons LMG, Farina Sarasqueta A et al. Long-term oncological outcomes of endoscopic full-thickness resection after previous incomplete resection of low-risk T1 CRC (LOCAL-study): study protocol of a national prospective cohort study. BMC Gastroenterol. 2022; 22; 516.
Zwager LW, Bastiaansen BAJ, Montazeri NSM et al. Deep submucosal invasion is not an independent risk factor for lymph node metastasis in T1 colorectal cancer: a meta-analysis. Gastroenterology 2022; 163; 174-189.
Moss SM, Campbell C, Melia J et al. Performance measures in three rounds of the english bowel cancer screening pilot. Gut 2012; 61; 101-107.
Anderson JC, Butterly LF, Robinson CM, Weiss JE, Amos C, Srivastava A. Risk of metachronous high-risk adenomas and large serrated polyps in individuals with serrated polyps on index colonoscopy: data from the New Hampshire Colonoscopy Registry. Gastroenterology 2018; 154; 117-127.e2.
Hazewinkel Y, Lopez-Ceron M, East JE et al. Endoscopic features of sessile serrated adenomas: validation by international experts using high-resolution white-light endoscopy and narrow-band imaging. Gastrointest. Endosc. 2013; 77; 916-924.
Bouwens MWE, van Herwaarden YJ, Winkens B et al. Endoscopic characterization of sessile serrated adenomas/polyps with and without dysplasia. Endoscopy 2014; 46; 225-235.
East JE, Vieth M, Rex DK. Serrated lesions in colorectal cancer screening: detection, resection, pathology and surveillance. Gut 2015; 64; 991-1000.
Pai RK, Makinen MJ, Rosty C. Colorectal serrated lesions and polyps. In Nagtegaal ID, Arends MJ, Odze RD eds. WHO classification of tumours: digestive system tumours. Lyon: IARC, 2019.
Snover DC, Ahnen DJ, Burt RW et al. Serrated polyps of the colon and rectum and serrated polyposis. In Bosman FT, Carneiro F, Hruban RH, Theise ND eds. WHO classification of tumours of the digestive system. Lyon: IARC, 2010.